Anzeige
Mehr »
Login
Freitag, 03.02.2023 Börsentäglich über 12.000 News von 679 internationalen Medien
Breaking News! Startup wird zum Pionier!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A11664 ISIN: US03209R1032 Ticker-Symbol: 29A 
Tradegate
02.02.23
19:49 Uhr
28,200 Euro
-0,400
-1,40 %
1-Jahres-Chart
AMPHASTAR PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
AMPHASTAR PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
28,40028,80008:56
28,40028,80008:40

Aktuelle News zur AMPHASTAR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
AMPHASTAR Aktie jetzt für 0€ handeln
22.11.22Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference521RANCHO CUCAMONGA, CA / ACCESSWIRE / November 22, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, Sr. Vice President Regulatory Affairs and...
► Artikel lesen
18.11.22Amphastar Pharmaceuticals, Inc. - 8-K, Current Report2
10.11.22Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the 2022 Jefferies London Healthcare Conference348RANCHO CUCAMONGA, CA / ACCESSWIRE / November 10, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Jacob Liawatidewi, Executive V.P. of Corporate Administration...
► Artikel lesen
08.11.22Amphastar authorizes $50M buyback2
07.11.22Amphastar Pharmaceuticals Non-GAAP EPS of $0.38 misses by $0.01, revenue of $120.13M misses by $6.27M2
07.11.22Amphastar Pharmaceuticals, Inc. - 8-K, Current Report1
07.11.22Amphastar Pharmaceuticals Q3 2022 Earnings Preview1
28.10.22Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 7, 2022263RANCHO CUCAMONGA, CA / ACCESSWIRE / October 28, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2022 ended September 30...
► Artikel lesen
16.08.22Amphastar wins FDA approval for Epinephrine pre-filled syringes2
16.08.22Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals Receives FDA Approval for Epinephrine Pre-Filled Syringes372RANCHO CUCAMONGA, CA / ACCESSWIRE / August 16, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's New Drug Application...
► Artikel lesen
09.08.22Amphastar Pharmaceuticals, Inc. - 8-K, Current Report1
09.08.22Amphastar sheds 14% after announcing FDA rejection of generic drugs5
08.08.22Amphastar Pharmaceuticals Non-GAAP EPS of $0.39 beats by $0.04, revenue of $123.47M beats by $5.59M1
08.08.22Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2022338Reports Net Revenues of $123.5 Million for the Three Months Ended June 30, 2022RANCHO CUCAMONGA, CA / ACCESSWIRE / August 8, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the...
► Artikel lesen
01.08.22Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2022301RANCHO CUCAMONGA, CA / ACCESSWIRE / August 1, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2022 ended June 30, 2022...
► Artikel lesen
19.07.22Amphastar Pharmaceuticals, Inc.: Amphastar Receives FDA Approval for Vasopressin932RANCHO CUCAMONGA, CA / ACCESSWIRE / July 19, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated...
► Artikel lesen
06.06.22Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference432RANCHO CUCAMONGA, CA / ACCESSWIRE / June 6, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, and Dan Dischner, V.P of Corporate Communications...
► Artikel lesen
24.05.22Amphastar Pharmaceuticals, Inc.: Amphastar Receives FDA Approval for Regadenoson390RANCHO CUCAMONGA, CA / ACCESSWIRE / May 24, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New...
► Artikel lesen
09.05.22Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2022258Reports Net Revenues of $120.4 Million for the Three Months Ended March 31, 2022RANCHO CUCAMONGA, CA / ACCESSWIRE / May 9, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company")...
► Artikel lesen
02.05.22Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2022365RANCHO CUCAMONGA, CA / ACCESSWIRE / May 2, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2022 ended March 31, 2022, after...
► Artikel lesen
Seite:  Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1